Category: Mid Day Movers

Shares of the Aehr Test Systems (AEHR) stock were gloomy in the current market trading session today on January 10, 2022. AEHR stock price saw a downtrend of11.80% to drop at $14.19 a share at the time of this writing. The stock was also down in the previous trading session and recorded a decline of 21.44% at closing. Let’s look at the culprit behind this drop.

What’s Happening?

Aehr Test System recently announced the second quarter of fiscal 2022 financial results on January 6, 2022. The company reported record sales in the reported quarter. Even then the AEHR stock is facing a decline in the stock market. Actually, AEHR stock outperformed in 2021 as the per-share price of the stock rose more than 800%. Hence the profit takers have stepped in to start their new year with a massive profit. This resulted in the per-share decline of the AEHR stock even after the release of strong quarterly results.

Second Quarter Fiscal 2022 Financial Results

• In the second quarter of the fiscal year 2022, the company generated $9.6 million in net sales. This represents a whopping 471% increase from the same quarter of last year.
• The GAAP net income of the AEHR stock was $0.03 per diluted share or $717,000 in the recently reported quarter. This compares to GAAP net loss of 2.0 million or $0.08 per diluted share in the same quarter of the previous year.
• Non-GAAP net income in the second quarter of the fiscal year 2022 was $1.4 million, or $0.05 per diluted share for the AEHR stock. In the same tenure of the previous year, the non-GAAP net loss was $1.7 million, or $0.07 per diluted share.
• The company reported the highest bookings of $29.1 million in the reported quarter as compared to $1.6 million in the same prior-year quarter.
• By the end of the quarter, the company had $36.1 million in the backlog.

Fiscal First Six Month Financial Results of AEHR stock

In the first six months of the fiscal year 2022, the company recorded net sales of $15.3 million, 313% higher than $3.7 million in the same period of the previous year. GAAP net income in this period was $1.4 million, or $0.05 per diluted share of AEHR stock. Non-GAAP net income was $1.0 million, or $0.04 per diluted share in the first six months of the fiscal year 2022.

Wrap Up

Though the AEHR stock is gloomy, its financial results reflect strong growth of the company and hence it can be a good bet for investors in the long run.

Shares of the Atai Life Sciences N.V. (ATAI) stock were rising in the current market trading session today on January 7, 2022. ATAI stock price saw a push of 0.61% to reach $6.64 a share at the time of this writing. The trading volume on the last check was 397,494. Let’s deep dive to understand the reason behind this rally.

What’s Happening?

ATAI stock is hot among investors in the stock market today however there is no specific news associated with this rise.  There is no press release or any announcement by Atai Life Sciences to justify the current bullish sentiment. No analyst has upgraded or increased the per-share target price of ATAI stock in recent times. It seems that the stock is getting the push due to discussions among investors on the social media platforms like Reddit, StockTwits, Twitter, etc. So, what do you need to know now at this point, let’s discuss some recent events of ATAI stock?

Recent event of ATAI stock

Atai Life Sciences’ recent program atai Impact previously on December 16, 2021, announced the establishment of the Fellowship Fund in Psychedelic Neuroscience. The company announced this fellowship program in collaboration with Massachusetts General Hospital’s (MGH) Center for the Neuroscience of Psychedelics.

The Fellowship program will increase the research on psychedelics in order to meet the needs of the patients. The graduate student will be able to take benefit from this program.

The company launched the atai Impact in October 2021, the purpose of which is to expand the mental health care ecosystem. Atai impact is initially focusing on psychedelics.

Financial View of ATAI stock

According to the third quarter of 2021 financial results, the company spent $13.4 million in research and development expenses. In the first nine months of 2021, research and development expenses reached $35.0 million. Research and development expenses significantly increased in these periods as compared to respective periods in the previous year. This represents positive growth of the company which is a good sign for long-term shareholders of ATAI stock.

General and administrative expenses in the third quarter of 2021 were $20.3 million as compared to $4.3 million in the same tenure of the previous year. In the first nine months of 2021, the company spent $66.9 million in general and administrative expenses.

Net loss of the ATAI stock was $31.2 million in the third quarter of 2021. Net loss for the first nine months of 2021 was $78.9 million. The company ended the quarter with

Shares of the Nisun International Enterprise Development Group Co., Ltd (NISN) stock rallied in the current market trading session today on January 7, 2022. NISN stock price saw a push of 3.59% to reach $2.88 a share at the time of this writing. The stock was also green in the previous trading session and went up by 12.55% at closing. Let’s understand the reason behind this rise.

What’s Happening?

Nisun International recently announced that the company has entered into the supply chain agreement Henan Shiwugu Co., Ltd. The company will help Henan Shiwugu in broadening its market share under this agreement. Nisun will follow its policy to import grain products under this agreement, providing procurement and other services. Investors in response to this news showed interest in NISN stock which resulted in the increase in per-share price.

In order to improve the efficiency and optimize resource integration in the supply chain of Shiwugu, Nisun will completely mobilize and integrate market resources. The company will support the Shiwugu by importing grains as well as agricultural products from the overseas market. The company will fully rely on its sufficient capital resources in this whole process. The company will continue to support small and medium-size enterprises through its tailored services.

Previously Development of NISN stock

The company previously on December 31, 2021, did announce the cooperation supply chain agreement with Henan Huangchuan Biandijin AGRI-FOOD., LTD. Under the agreement, the former will provide procurement services for grain and oil products.

The company in December also signed the strategic cooperation agreement with ichuan Wanglianxing Agricultural Technology Development Co., Ltd. and Henan Xingyue Communication Technology Co., Ltd in order to cooperate in the supply chain trade of agricultural products.

Offering of NISN stock

On December 15, 2021, Nisun International did announce that it has closed the underwritten public offering of class A common shares and warrants to buy class A common shares. The company offered 19.5 million class A shares of NISN stock which resulted in $77 million gross proceeds before underwriter discounts and offering related expenses. Nisun International will use the net proceeds working capital, business opportunities as well as for general corporate purposes.

Wrap Up

The sentiment is positive for NISN stock in the stock market so far. It would be interesting to see how long this stock will continue to rise as the stock market is highly unpredictable. It is better to analyze the company’s fundamentals and future development before making any investment decision.

Shares of the Bed Bath & Beyond Inc. (BBBY) stock were popping high in the current market following the announcement of the third quarter of 2021 financial results. BBBY stock price saw a surge of 7.30% to reach $14.34 a share at the time of this writing. The trading volume on the last check was 24,168,082, far higher than the average trading volume. Let’s deep dive to explore more of it.

Q3 Highlights of BBBY stock

According to the third quarter of fiscal 2021 ended November 22, 2021,

• Net sales of the company in the reported quarter were $1,878 million, representing a 28% decline from the comparable period of the previous year. Comparable sales showed a decline of 7% as compared to the same period of the previous year.
• GAAP gross margin in the third quarter of 2021 was 35.6% for the BBBY stock. The company reported an adjusted GAAP gross margin of 35.9% in the reported quarter. This represents an improvement of 320 basis points in merchandise margin from the same period of the previous year.
• Net loss per diluted share of the BBBY stock was $2.78 in the recently reported quarter. It reflects $2.53 of special items for the reported quarter.
• Operating cash flow in the third quarter of fiscal 2021 was $0.3 billion for the BBBY stock.
• As of December 25, 2021, the company had $0.7 billion in cash and cash equivalents. Total liquidity as of December 25, 2021, was approximately $1.6 billion.

Outlook of BBBY stock

• The company expects $2.1 billion in net sales in the fourth quarter of 2021. For the fiscal year 2021, the company is hoping to record $7.9 billion in net sales.
• BBBY projected the adjusted gross margin between  32.5% to 33.0% for the fourth quarter of 2021. Adjusted gross margin for the full fiscal year 2021 is expected in the range of 34.0% to 34.5%. The company is anticipating 34% adjusted SG&A for the fiscal year 2021.
• BBBY estimated the adjusted EBITDA in the range of $80 million to $100 million for the fourth quarter of 2021. The adjusted EBITDA for the full year 2021 is expected to be between $290 million to $310 million.

Wrap Up

Though the financial results fell short of the analysts’ expectations, BBBY stock still climbed up in the current market. As the management has warned of the potential loss for the full year, investors need to be cautious before adding this stock to their portfolio.

Shares of the Freeline Therapeutics Holdings plc (FRLN) stock were soaring in the current market trading session today on January 6, 2022. FRLN stock price saw a surge of 12.24% to reach $2.20 a share at the time of this writing. The stock was gloomy in the previous trade and went down by 3.45% at closing. Let’s deep dive to understand the current bullish sentiment.

What’s Happening?

There is indeed a piece of positive news behind the rise in the per-share price of the FRLN stock. The company reported that the U.S Food and Drug Administration has cleared the New Drug application for FLT201. Thinking about FLT201? It is the gene therapy to treat patients with Gaucher disease Type 1. This is an important milestone for the company and positive news for the shareholders of FRLN stock.

Freeline at the end of 2021 started Phase 1/2 dose-finding trial of FLT201. The company is hoping for the first dose cohort in which it will dose two patients in the first quarter of 2022. The initial safety and biomarker data from the first dose cohort is expected in the third quarter of 2022. The company is expecting to release the data of all dosed patients before the end of the year 2022.

What’s next for FRLN stock?

According to Freeline’s officials, the company aims to advance the development of therapies in the year 2022. The management is hopeful that the company will deliver best-in-class or first-in-class treatments as the focus is on the long-term success of the company as well as FRLN stock.

The company is advancing the FLT180a for hemophilia B at a fast pace and enrolled sufficient numbers of patients for the trial already. The focus this year will be the dosing of the patients. The company believes that the FLT180a is a potentially strong treatment for hemophilia B.

Freeline is also looking forward to advancing the FLT190 for the patients with Fabry disease in this entire year. The goal in 2022 is to add additional patients to the dosing process in order to gather the data. The company reported that it will dose the third patient in the ongoing clinical trial within the first six months of 2022.

Wrap Up:

Investors are happy with the recent announcement of Freeline Therapeutics and responding positively towards FRLN stock. Investors having long-term prospects need to keep an eye on this stock.

Shares of the BTCS Inc. (BTCS) stock were surging in the current market trading session today on January 5, 2022. BTCS stock price saw a push of 44.06% to reach $4.36 a share at the time of this writing. The trading volume on the last check was 5,253,465, far higher than the average trading volume. Let’s take a closer look at this stock to understand the current bullish sentiment.

What’s Happening?

BTCS stock got positive momentum today after the company announced that it will pay the bividend(dividend) to the shareholders in the form of Bitcoin. This announcement makes BTCS Inc the first-ever Nasdaq listed company that will pay the dividend in the form of Bitcoin. The company has referred this form of dividend as a bividend. The company is on a mission to promote the adoption of cryptocurrency and blockchain technology.

How much Dividend?

Shareholders of record date at their election in Bitcoin or cash, of BTCS stock will receive the $0.05 per share in Bitcoin, depending on the Bitcoin price on the ex-dividend date. If you want to know more about the company and its future growth plans, you can visit www.btcs.com, where the company has published the new investor presentation.

New Appointment by BTCS stock:

At the beginning of December 2021, the company announced that it has appointed Michael Prevoznik as Chief Financial Officer of the Company. Mr. Prevoznik served PricewaterhouseCoopers LLP for more than nine years before joining the BTCS. The management is optimistic that this appointment will help in its new phase of corporate development.

Financial view of BTCS stock:

According to third-quarter 2021 financial results, the revenue for the three months ended September 2021 was $0.3 million. The revenue for the first nine months of 2021 was $0.8 million. The gross margin in the recently reported quarter was 81% for the BTCS stock. The company reported a GAAP net loss of $3.8 million in the third quarter of 2021. This loss was $15.5 million in the same tenure of the previous year. By the end of the third quarter, Stockholder’s equity improved to  $8.48 million from  $7.4 million as of December 31, 2020.

Wrap Up:

Investors are responding positively towards the BTCS stock after the bividend announcement. The recent events and financial results reflect the positive growth of the company. In a nutshell, BTCS stock can be a good bet for investors in the long run.

Shares of the Connect Biopharma Holdings Limited (CNTB) stock were gloomy in the current market trading session today on January 5, 2022. CNTB stock price saw a downtrend of 8.25% to drop at $5.23 a share at the time of this writing. The stock was also gloomy in the previous trade and went down by 3.72% at closing.

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company based in Taicang, China. The company discovers and develops immune modulators in order to treat serious autoimmune diseases and inflammation. CNTB stock has a current market value of $327.65 million and a 373,677 average trading volume. Let’s dig in to understand the reason behind the current fall.

What’s Happening?

Connect Biopharma today announced positive detailed data from the phase global Phase 2b clinical trial of CBP-201. The study team evaluated the CBP-201 in adults patients suffering from moderate to severe atopic dermatitis. The data from the results suggest that CBP-201 has shown favorable safety data and is in line with the efficacy expectations.

The topline results from the phase 2b trial indicate that all three CBP-201 arms met the primary endpoint and were statistically superior to placebo. The recently reported results meet the expectations, even then the per-share price of the CNTB stock is declining in the current market today.

New Appointment by CNTB stock

On November 22, 2021, the company announced that it had appointed Mr. Steven Chan as Chief Financial Officer of the company. Mr. Steven has profound experience of more than 25 years in financial leadership. He worked across many industry sectors that include biotechnology, healthcare, financial services, consumer products, and manufacturing.

CBP-307 Global Phase 2 Clinical Trial:

In the Global Phase 2 Clinical Trial of CBP-307, the company is evaluating adult patients suffering from moderate-to-severe Ulcerative Colitis. The purpose of the trial is to evaluate the safety and efficacy of CBP-307 in 134 subjects. Connect Biopharma on November 19, 2021, did announce that it had completed the enrollment of the concerned trial. This indicates that the company’s clinical developments are progressing which is a good sign for the shareholders of CNTB stock.

Wrap Up:

CNTB stock is gloomy despite positive results from the phase 2b clinical trial of CBP-201. Investors eying this stock need to do deep research before making any decision.

Shares of the Soligenix, Inc. (SNGX) stock were rising in the current market trading session today on January 4, 2022. SNGX stock price saw a push of 12.08% to reach $0.77 a share at the time of this writing. The trading volume was 7,953,965 on the last check, far higher than the average trading volume. Let’s take a closer look at SNGX stock to understand the current bullish sentiment.

What’s Happening?

SNGX stock became bullish after the company reported the effectiveness of the dusquetide in reducing tumor size in nonclinical xenograft models. The results from the studies demonstrated the efficacy of dusquetide as a standalone anti-tumor therapy. In Phase 2 clinical trial, Dusquetide proved to be effective in reducing severe oral mucositis duration. In Phase 3 clinical trial, Dusquetide reduced the SOM rates in the per-protocol population.

Soligenix will continue to explore the opportunities of dusquetide in both reductions of oral mucositis as well as an anti-cancer treatment. The product also showed increased overall survival and speedy clearance of tumor response in the Phase 2 clinical trial. Such results are not only creating a positive impact for the company but also adding value for the shareholders of SNGX stock.

Financial View of SNGX stock:

• According to third-quarter 2021 financial results, the company generated $0.2 million in revenue in the reported period. This compares to $0.6 million in revenue in the same tenure of the previous year.
• Basic net loss in the third quarter of 2021 was $3.6 million as compared to $1.8 million in the same quarter of last year.Net loss per share of the SNGX stock was $0.09 per share.
• The company spent $2.5 million in research and development expenses in the third quarter of 2021. These expenses were $1.3 million in the same period of the previous year.
• General and administrative expenses of the company were $0.9 million in the recently reported quarter. In the same quarter of the previous year, these expenses were $0.8 million.
• Soligenix ended the third quarter of 2021 with $29 million in cash position.

Wrap Up:

Investors are responding positively to the SNGX stock after the recent announcement by the company regarding dusquetide. The sentiment for this stock is positive in the social media communities resulting in an increase in the per-share price. However, the stock has lost 1.26% in the last thirty days and 41.21% in the last six months.

Shares of the Hoth Therapeutics, Inc. (HOTH) stock were rising in the current market trading session today on January 4, 2022. HOTH stock prices saw a push of 89.47% to reach $1.34 a share at the time of this writing. The stock was also green in the previous trade and went up by 6.90% at closing. Let’s dig in to know the reason behind this bull.

What’s Happening?

HOTH stock continued the bullish momentum after the company announced the data for HT-ALZ Therapeutic.  Hoth Therapeutics conducted the study at Washington University in St. Louis. HT-ALZ is intended to treat dementia related to Alzheimer’s disease. According to the initial data from the study, treatment of both male and female APP/PS1+/- mice with HT-ALZ resulted in a significant decrease in Aβ compared to placebo. The results support the potential of HT-ALZ to modify Aβ plaque formation in the brain.

The results are encouraging for both company and shareholders of the HOTH stock. Overall positive results are the big step in the development of HT-ALZ as a therapeutic for Alzheimer’s disease. Now the next task of the company is to observe the changes that happened due to HT-ALZ in mice. The company will observe the influence of these changes in behavior and cognitive function.

Previous News of HOTH stock

On December 21, 2021, Hoth Therapeutics confirmed the submission of an Orphan Drug Designation Request to the US Food and Drug Administration (FDA) for HT-KIT to treat mastocytosis. HT-KIT results in apoptosis of neoplastic mast cells via targeting proto-oncogene cKIT.

Drugs that treat orphan diseases are applicable for Orphan Drug Designation (ODD). The sponsor gets multiple benefits from ODD during the development and after approval.

Agreement with Zylö Therapeutics

On December 8, 2021, Hoth did announce that it had signed an agreement with Zylö Therapeutics to license its novel cannabinoid therapeutics, HT-005 for lupus patients, back to Zylö. HT-005 licensing back to Zylö is a win-win situation for both the companies as it proved its safety and efficacy in animals. Zylö will bear the further development cost for the therapeutics thus reducing the cost burden on Hoth stock.

Conclusion

So far so good for HOTH stock as far as market sentiment is concerned. The company is progressing in terms of its operations. In the past six months, the stock has lost 9.21%. In a nutshell, deep research is necessary before adding this stock to the portfolio.

Shares of the Creative Medical Technology Holdings, Inc. (CELZ) stock were soaring in the current market trading session today on January 3, 2022. CELZ stock price saw an uptrend of 40.27% to reach $3.10 a share at the time of this writing. The trading volume was 37,224,151 on the last check, far higher than the average trading volume.

Creative Medical Technology Holdings, Inc is a biotech company that is engaged in the development of urology, orthopedics, and neurology using adult stem cell treatments. CELZ stock has a market cap of $21.38 million market cap and a 725,863 average trading volume. Let’s deep dive to understand the reason behind the current rally.

What’s Happening?

CELZ has captivated the attention of investors in the stock market today. However, there is no stock-specific news to support the bullish sentiment. there is no press release or any announcement by the company to back the current positive momentum. No analyst has upgraded or increased per share target price of CELZ stock in recent times. From the social media analysis, it seems that this stock is hot among investors in the social media platforms like Reddit, Stock Twits, Twitter, etc. The discussions among investors are driving the per-share price of CELZ stock in today’s current market. For your intuition, lets discuss some recent events of Creative Medical Technology Holdings.

Report of ImmCelz™ Immunotherapy Product:

On October 12, 2021, the company reported proof of concept that demonstrated ImmCelz™ immunotherapy product’ ability to “reprogram” immune cells of the patient via “ex vivo cell-free” reprogramming protocol.” The company performed the study at the University of Miami, Miami FL. The Cure Alliance, a non-profit research organization supported the study.

ImmCelz™ provides the specific characteristics of the immune cells of the patient. For this purpose, it uses adult stem cells of qualified donors. After the incubation of immune cells with the company’s reprogramming cocktail, the immune cells are extracted and again injected into patients. Thus, these cells educate other cells to resist the foreign pathogens that can cause cancer.

Conclusion:

Things are going well for CELZ stock despite the absence of any stock-specific news. It would be interesting to see how long this trend will remain as the stock market is highly unpredictable. It is better to do fundamental as well as technical analysis before making any decision.